Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01011972 · ClinicalTrials.gov registry record · Phase 1
A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Mersana Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT01011972 is a Phase 1 study that has completed, run by Mersana Therapeutics. The registered enrollment target is 52 participants.
The verdict
NCT01011972, a Phase 1 study, has completed, sponsored by Mersana Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
XMT-1107 has been shown in nonclinical studies to slow the growth of tumors. These effects may result from blocking the growth of new blood vessels that help the tumors survive.
Interventions
- DRUG XMT-1107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-03 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01011972
The ClinicalTrials.gov registry entry for NCT01011972 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mersana Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XMT-1107 is the first listed.
NCT01011972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01011972 about?
NCT01011972 is a clinical study titled "A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors". XMT-1107 has been shown in nonclinical studies to slow the growth of tumors. These effects may result from blocking the growth of new blood vessels that help the tumors survive.
What is the current status of trial NCT01011972?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2010-03. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01011972?
The interventions under investigation include: XMT-1107 (DRUG).
Who is sponsoring clinical trial NCT01011972?
This trial is sponsored by Mersana Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.